1
|
Metcalfe C, Zhou W, Guan J, Daemen A, Hafner M, Blake RA, Ingalla E, Young A, Oeh J, De Bruyn T, Ubhayakar S, Chen I, Giltnane JM, Li J, Wang X, Sampath D, Hager JH, Friedman LS. Abstract GS3-05: Prospective optimization of estrogen receptor degradation yields ER ligands with variable capacities for ER transcriptional suppression. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs3-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
ER+ breast cancers can depend on ER signaling throughout disease progression, including after acquired resistance to existing endocrine agents, providing a rationale for further optimization and development of ER-targeting agents. Fulvestrant is unique amongst currently approved ER ligand therapeutics due to classification as a full ER antagonist, which is thought to be achieved through degradation of ER protein. However, the full clinical potential of fulvestrant is believed to be limited by poor bioavailability, spurring attempts to generate ligands capable of driving ER degradation but with improved drug-like properties.
Here, we evaluate three ER ligand clinical candidates that recently emerged from prospective optimization of ER degradation – GDC-0810, AZD9496 and GDC-0927 - and show that they display distinct mechanistic features. GDC-0810 and AZD9496 are more limited in their ER degradation capacity relative to GDC-0927 and fulvestrant, display evidence of weak transcriptional activation of ER in breast cancer cells (i.e. partial agonist activity), and do not achieve the same degree of in vitro anti-proliferative activity as GDC-0927 and fulvestrant. In the HCI-013 (ER.Y537S) and HCI-011 (ER.WT) ER+ patient-derived xenograft models, GDC-0927 drives greater transcriptional suppression of ER, and greater anti-tumor activity relative to GDC-0810.
We found that despite their full antagonist phenotype, GDC-0927 and fulvestrant promote association of ER with DNA, including at canonical ERE motifs, prior to ER degradation. Interestingly however, integration of ER ChIP-Seq and ATAC-Seq data revealed that ER complexed with fulvestrant or GDC-0927 fails to increase chromatin accessibility at DNA binding sites, in contrast to partial agonists which result in increased chromatin accessibility at ER binding sites. Thus, although ER contacts DNA when engaged with fulvestrant and GDC-0927, it is functionally inert. To further explore mechanistic features that might account for the differential activity of full antagonists and partial agonists that occurs prior to ER degradation, we used cell-based florescence recovery after photobleaching (FRAP) to measure the kinetics of ER diffusion within the nucleus. We demonstrate that while ER is generally highly mobile, including after engagement with GDC-0810 and AZD9496, GDC-0927 and fulvestrant immobilize intra-nuclear ER. A site saturating mutagenesis screen revealed a series of novel ER mutations that prevent ER immobilization by fulvestrant and GDC-0927. This class of “always mobile” ER variants promotes an antagonist-to-agonist transcriptional switch for fulvestrant and GDC-0927, and simultaneously prevents ER degradation by these molecules, implying that ER immobilization is a key functional determinant of robust transcriptional suppression.
We thus propose that ER degradation is not a driver of full ER antagonism, but rather a downstream consequence of ER immobilization, occurring after a suppressive phenotype has been established at chromatin. We additionally argue that evaluating the transcriptional output of candidate ER therapeutics, both pre-clinically and clinically, will be critical for the identification of ER ligands with best-in-class potential.
Citation Format: Metcalfe C, Zhou W, Guan J, Daemen A, Hafner M, Blake RA, Ingalla E, Young A, Oeh J, De Bruyn T, Ubhayakar S, Chen I, Giltnane JM, Li J, Wang X, Sampath D, Hager JH, Friedman LS. Prospective optimization of estrogen receptor degradation yields ER ligands with variable capacities for ER transcriptional suppression [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS3-05.
Collapse
Affiliation(s)
- C Metcalfe
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - W Zhou
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - J Guan
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - A Daemen
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - M Hafner
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - RA Blake
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - E Ingalla
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - A Young
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - J Oeh
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - T De Bruyn
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - S Ubhayakar
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - I Chen
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - JM Giltnane
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - J Li
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - X Wang
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - D Sampath
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - JH Hager
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| | - LS Friedman
- Genentech, South San Francisco; University of California San Francisco, San Francisco; Ideaya Biosciences, San Diego
| |
Collapse
|
2
|
Young A, Crocker L, Cheng E, Lacap J, Hamilton P, Oeh J, Ingalla E, Arrazate A, Hager J, Nannini M, Friedman L, Daemen A, Giltnane J, Sampath D. Abstract P4-06-05: Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-06-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The phosphoinositide 3-kinase (PI3K) pathway is a key driver of hormone receptor (HR)–positive breast cancer growth and survival. It is estimated that 40-45% of HR+ breast cancers harbor oncogenic mutations in the PIK3CA gene, which encodes the p110α isoform of PI3K. Taselisib (GDC-0032) is a mutant-selective PI3K inhibitor that demonstrates enhanced potency in PIK3CA mutant breast cancer cells and is being developed as a treatment for metastatic breast cancer that targets PIK3CA-mutant, HR-positive, HER2-negative patients. Activating mutations in the ESR1 gene were recently described in metastatic breast cancer. These mutations confer hormone independent growth and may be associated with resistance to aromatase inhibitors. Drugs that selectively bind and antagonize the Estrogen Receptor alpha (ERα) protein and target it for degradation, such as fulvestrant, are referred to as selective estrogen receptor degraders (SERDs). Preclinical activity of the orally bioavailable SERD, GDC-0810, has not been well characterized in ESR1 mutant PDX models. Therefore, our aim was to evaluate the efficacy and pharmacodynamic responses to agents that target ERα and PI3K as monotherapies and in combination, in ESR1 and PIK3CA mutant HR+ breast cancer patient-derived xenograft (PDX) models. We hypothesized that mutational status of ESR1 and PIK3CA may predict the responsiveness of HR+ PDX models to SERDs and PI3K inhibitors in vivo. Characterization of seven PDX models included authentication of hormone receptor status by immunohistochemistry (IHC) and determination of ESR1 and PIK3CA genotype and allele frequency by exome sequencing. For a subset of models that utilize estrogen for growth, mice were supplemented with 17β-estradiol, and cells or tumor fragments were implanted into the fat pad of intact female NOD-SCID or NOD-SCID-IL2Rgamma null mice and treated with fulvestrant, GDC-0810, or taselisib. Both fulvestrant and GDC-0810 were efficacious in ESR1 wild type (WT) and mutant PDX models but to variable degrees ranging from tumor stasis to growth delay, with GDC-0810 resulting in superior single agent activity at relevant clinical exposure in the WHIM20 and WHIM43 ESR1 mutant models. PIK3CA mutations (E542K, E545K, M1004V, and H1047R) were confirmed in six PDX models and PI3K pathway activation verified by strong pS6RP IHC staining. Taselisib induced tumor growth inhibition and tumor regressions in models harboring PIK3CA mutations, and models with no detectable expression of WT p110α were the most sensitive. In the WHIM43 (ESR1 D538G, PIK3CA M1004V), HCI-011 (ESR1 WT, PIK3CA E545K) and HCI-013 (ESR1 Y537S, PIK3CA H1047R) PDX models, combining fulvestrant and taselisib treatment further enhanced tumor growth inhibition with respect to either treatment alone. Our studies demonstrate the diverse anti-tumor responses of HR+ PDX models to SERDs and the PI3K inhibitor taselisib in the context of clinically relevant ESR1 and PIK3CA mutations. Pharmacological and genomic characterization of additional PDX models may aid in strengthening associations between genotype, drug sensitivity and predictive biomarkers of response.
Citation Format: Young A, Crocker L, Cheng E, Lacap J, Hamilton P, Oeh J, Ingalla E, Arrazate A, Hager J, Nannini M, Friedman L, Daemen A, Giltnane J, Sampath D. Treatment of ESR1 mutant and PIK3CA mutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitors in vivo [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-06-05.
Collapse
Affiliation(s)
- A Young
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - L Crocker
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - E Cheng
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Lacap
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - P Hamilton
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Oeh
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - E Ingalla
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - A Arrazate
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Hager
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - M Nannini
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - L Friedman
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - A Daemen
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - J Giltnane
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| | - D Sampath
- Genentech, Inc.; Seragon Pharmaceuticals, Inc
| |
Collapse
|